ALX Oncology Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by ALX Oncology Holdings Inc. on June 10, 2021. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol ALXO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Proposal 1: Election of Three Class I Directors
- Corey Goodman, Ph.D.: Elected (33,898,340 For; 2,307,647 Withheld)
- Jason Lettmann: Elected (33,911,262 For; 2,294,725 Withheld)
- Sophia Randolph, M.D., Ph.D.: Elected (35,309,396 For; 896,591 Withheld)
- All nominees were elected to serve until the 2024 annual meeting.
- Proposal 2: Ratification of Independent Registered Public Accounting Firm
- KPMG LLP was ratified as the independent auditor for the fiscal year ending December 31, 2021.
- Voting Results: 37,458,731 For; 4,303 Against; 2,137 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the three newly elected Class I Directors and their tenure until 2024.
- Verification of KPMG LLP's appointment as the independent auditor for the 2021 fiscal year.
- Review of the total shares voted and broker non-votes to assess shareholder engagement levels.